PD-L1-driven tolerance protects neurogenin3-induced islet neogenesis to reverse established type 1 diabetes in NOD mice

Diabetes

Volumn 64, Issue 2, 2015, Pages 529-540

  Li, Rongying ^a   Lee, Jeongkyung ^a   Kim, Mi Sun ^a   Liu, Victoria ^a   Moulik, Mousumi ^b   Li, Haiyan ^c   Yi, Qing ^c   Xie, Aini ^a   Chen, Wenhao ^a   Yang, Lina ^a   Li, Yimin ^a   Tsai, Tsung Huang ^a   Oka, Kazuhiro ^a   Chan, Lawrence ^a   Yechoor, Vijay ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETACELLULIN; C PEPTIDE; GAMMA INTERFERON; INSULIN; NEUROGENIN 3; PROGRAMMED DEATH 1 LIGAND 1; PROINSULIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CD274 PROTEIN, MOUSE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; NERVE PROTEIN; NEUROG3 PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL CELL; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE STUDY; CYTOKINE PRODUCTION; DIABETOGENESIS; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TRANSFER; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LIVER; LONG TERM SURVIVAL; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; SPLEEN CELL; VIRAL CLEARANCE; WEIGHT GAIN; WESTERN BLOTTING; ANIMAL; CYTOLOGY; GENETICS; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; NONOBESE DIABETIC MOUSE; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD274; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 1; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS; MICE; MICE, INBRED NOD; NERVE TISSUE PROTEINS; SPLEEN;

EID: 84921931326     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1737     Document Type: Article

References (49)

1. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006;355:1318-1330
2. Robertson RP. Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes 2010;59:1285-1291
3. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007;117:2553-2561
4. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003;198:63-69
5. Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T. Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A 2005;102:11823-11828
6. Martin-Orozco N, Wang YH, Yagita H, Dong C. Cutting edge: programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. J Immunol 2006;177:8291-8295
7. Guleria I, Gubbels Bupp M, Dada S, et al. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol 2007;125:16-25
8. Rajasalu T, Brosi H, Schuster C, et al. Deficiency in B7-H1 (PD-L1)/PD-1 coinhibition triggers pancreatic beta-cell destruction by insulin-specific, murine CD8 T-cells. Diabetes 2010;59:1966-1973
9. Fiorina P. β-Cells step up in controlling the autoimmune response. Diabetes 2010;59:1861-1864
10. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704
11. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-242
12. Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006;203:883-895
13. Keir ME, Freeman GJ, Sharpe AH. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol 2007;179:5064-5070
14. Lee I, Wang L, Wells AD, et al. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J Immunol 2003;171:6929-6935
15. Wang CJ, Chou FC, Chu CH, et al. Protective role of programmed death 1 ligand 1 (PD-L1) in nonobese diabetic mice: the paradox in transgenic models. Diabetes 2008;57:1861-1869
16. Yechoor V, Liu V, Espiritu C, et al. Neurogenin3 is sufficient for transdetermination of hepatic progenitor cells into neo-islets in vivo but not transdifferentiation of hepatocytes. Dev Cell 2009;16:358-373
17. Yechoor V, Liu V, Paul A, et al. Gene therapy with neurogenin 3 and betacellulin reverses major metabolic problems in insulin-deficient diabetic mice. Endocrinology 2009;150:4863-4873
18. Lee J, Kim MS, Li R, et al. Loss of Bmal1 leads to uncoupling and impaired glucose-stimulated insulin secretion in β-cells. Islets 2011;3:381-388
19. Zhang J, Dong Z, Zhou R, Luo D, Wei H, Tian Z. Isolation of lymphocytes and their innate immune characterizations from liver, intestine, lung and uterus. Cell Mol Immunol 2005;2:271-280
20. Miyahara Y, Khattar M, Schroder PM, et al. Anti-TCRb mAβ induces longterm allograft survival by reducing antigen-reactive T cells and sparing regulatory T cells. Am J Transplant 2012;12:1409-1418
21. Parks R, Evelegh C, Graham F. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 1999;6:1565-1573
22. Dorrell C, Erker L, Lanxon-Cookson KM, et al. Surface markers for the murine oval cell response. Hepatology 2008;48:1282-1291
23. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25 (Hi) regulatory T cells. Int Immunol 2009;21:1065-1077
24. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009;206:3015-3029
25. Shoda LK, Young DL, Ramanujan S, et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005;23:115-126
26. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698
27. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces longterm remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994;91:123-127
28. Belghith M, Bluestone JA, Barriot S, Mégret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003;9:1202-1208
29. Ablamunits V, Henegariu O, Hansen JB, et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012;61:145-154
30. Ogawa N, List JF, Habener JF, Maki T. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 2004;53:1700-1705
31. Simon G, Parker M, Ramiya V, et al. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 2008;57:405-414
32. Parker MJ, Xue S, Alexander JJ, et al. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 2009;58:2277-2284
33. Vergani A, D'Addio F, Jurewicz M, et al. A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes 2010;59:2253-2264
34. Tarbell KV, Petit L, Zuo X, et al. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 2007;204:191-201
35. Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010;207:1871-1878
36. Wang M, Racine JJ, Song X, et al. Mixed chimerism and growth factors augment b cell regeneration and reverse late-stage type 1 diabetes. Sci Transl Med 2012;4:133ra59
37. Wen X, Zhu H, Li L, et al. Transplantation of NIT-1 cells expressing pD-L1 for treatment of streptozotocin-induced diabetes. Transplantation 2008;86:1596-1602
38. Sung HH, Juang JH, Lin YC, et al. Transgenic expression of decoy receptor 3 protects islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice. J Exp Med 2004;199:1143-1151
39. Shieh SJ, Chou FC, Yu PN, et al. Transgenic expression of single-chain anti-CTLA-4 Fv on beta cells protects nonobese diabetic mice from autoimmune diabetes. J Immunol 2009;183:2277-2285
40. Huang SH, Chu CH, Yu JC, et al. Transgenic expression of haem oxygenase-1 in pancreatic beta cells protects non-obese mice used as a model of diabetes from autoimmune destruction and prolongs graft survival following islet transplantation. Diabetologia 2010;53:2389-2400
41. Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J Autoimmun 2010;34:1-6
42. Subudhi SK, Zhou P, Yerian LM, et al. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest 2004;113:694-700
43. Gao W, Demirci G, Strom TB, Li XC. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation 2003;76:994-999
44. Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009;10:1185-1192
45. Shternhall-Ron K, Quintana FJ, Perl S, et al. Ectopic PDX-1 expression in liver ameliorates type 1 diabetes. J Autoimmun 2007;28:134-142
46. Pauken KE, Jenkins MK, Azuma M, Fife BT. PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes. Diabetes 2013;62:2859-2869
47. Butte MJ, Peña-Cruz V, Kim MJ, Freeman GJ, Sharpe AH. Interaction of human PD-L1 and B7-1. Mol Immunol 2008;45:3567-3572
48. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007;27:111-122
49. Paterson AM, Brown KE, Keir ME, et al. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol 2011;187:1097-1105